Growthbridge ventures is an Investor Relations and Marketing Outreach firm. The companies listed on this website and Portal are not an offer to the general public to purchase any form of securities. Every company listed on this website and Portal are listed for Investor Relations and marketing outreach, and should be considered to be a very high risk investment and the investor must be comfortable in accepting and bearing the very high level of risk associated with any of the companies listed on this site, should they choose to engage in any form of investment. The information contained on these companies is proprietary and strictly confidential. It is intended to be reviewed only by accredited investors and financial institutions and should not be used for any other reason or made available to any other person or entity without the prior written consent of Growthbridge ventures. The technology and process used on this website is protected by existing or pending patents owned by Growthbridge ventures. Nothing on this site including any related communication is intended to provide specific financial, investment, tax, legal, accounting or other advice to you, and should not be acted or relied upon in that regard without seeking the advice of a professional. In all circumstances, you should seek guidance from your current advisor as your advisor can help to ensure that your own circumstances have been properly considered and any action is taken on the latest available information.
Meet
Pantheryx is a leading consumer health company developing science‑backed products primarily derived from bovine colostrum to improve gut, immune, and digestive health.
The company develops patented formulations, including its BovIgY™ colostrum‑egg technology, that it commercializes under category‑leading brands such as Relesium™, Bovy+™ and DiaResQ®. The Company also sells an established probiotics brand called Trubiotics.
With nationwide retail distribution, strong DTC channels, and a highly experienced leadership team, Pantheryx is positioned to scale rapidly across multiple high‑growth health categories.
Our flagship brands are BovIgY, Relesium And Bovy+. BovIgY is an ingredient brand we sell to other businesses seeking Colostrum based products. Relesium is a consumer brand including BovIgY shown to have a powerfully calming effect on digestive issues for those taking the GLP-1 drugs such as Ozempic and Mounjaro.
Bovy+ is another consumer product marketed as a lifestyle brand for consumers seeking colostrum supplementation for sports performance and general gut, immune, skin and hair health.
Problem They’re Solving
Over 60% of GLP‑1 patients experience significant GI side effects, yet there are no sustainable, physician‑recommended solutions that support long‑term adherence to these medications.
Pantheryx provides a clinically studied, all-natural companion product that relieves these symptoms without interfering with the drug’s mechanism of action.
At the same time, millions of consumers struggle with chronic digestive and immune issues and feel existing probiotics and digestive supplements have not delivered meaningful results, creating a clear need for more effective, science‑backed solutions.
Where They Are Headed
Pantheryx is focused on capturing the rapidly expanding gut‑health and microbiome markets through its patented BovIgY™ platform.
The company is launching two high‑potential brands—Bovy+ for the fast‑growing colostrum lifestyle category and Relesium as the first clinically studied GLP‑1 digestive companion product.
These categories represent more than $100B in combined market opportunity with exceptionally strong growth rates.
Pantheryx aims to establish leadership positions in both segments by leveraging its scientific credibility, retail presence, and differentiated product portfolio.
Opportunity Highlights
- Patented, Clinically Validated Products: Pantheryx offers differentiated, science‑backed formulations with proven efficacy, creating a defensible advantage over commodity competitors.
- Massive, High‑Growth Markets: The company operates across digestive, immune, microbiome, and GLP‑1 companion categories—representing over $100B in combined market size.
- High‑Margin, Scalable Infrastructure: Manufacturing partnerships and preferred supply agreements deliver 70%-90%+ gross margins with abundant capacity for rapid expansion.
- Experienced Leadership Team: A seasoned team with decades of success scaling nutrition and consumer health brands, enabling disciplined execution and accelerated growth.
- Established IP and Distribution Footprint: The Company has abundant science, formulation development and IP providing numerous cross-application sales opportunities with multiple products already sold through Walmart, Target, drug chains, Amazon, and DTC sites, providing immediate scale potential and national reach.
Management Team
Tom Feeley — CEO
Over 30 years in the nutrition industry, including scaling Martek Biosciences to $450M in revenue and a $1.1B acquisition. He brings deep expertise in hyper‑growth, commercialization, and category leadership.
Dr. Ray Playford — Medical Director
Globally recognized gastroenterologist and leading expert in colostrum science with 150+ peer‑reviewed publications. His clinical leadership anchors Pantheryx’s scientific credibility and product innovation.
Brian Budeselich — Senior VP Sales
25+ years of CPG sales experience with Novartis, DSM, and other multinationals. He has led multiple #1 brands and brings strong retailer relationships and national sales execution.
Milestones
- Ongoing: Numerous clinical studies completed with Patents granted on BovIgY™ colostrum + egg formulation
- Oct 2023: Colostrum collection & manufacturing business sold to Glanbia to focus on Driving Consumer Brands
- Nov 2024: Relesium observational clinical trial completed & published for GLP-1 GI Side Effects
- May 2025: Company Restructuring to eliminate debt and Prepare for New Consumer Brand Marketing Focus
- Q1 2026: Full launch of Relesium and Bovy+ with formulation & marketing collateral
Key Metrics
- Over two dozen retailers acquired with broad nationwide distribution including Walmart. Target and many grocery and drug chains
- Over 50 5-star online reviews with soft launch of new brand
- 70%-90% Gross Profit Margins in various channels with an umbrella of brands in gut and immune health
- Small infrastructure with little overhead for high EBITDA returns
Send us your contact information and our market specialist will reach out you.
